Carasent — Investor Presentation 2021

Oct 27, 2021

Interim report Q3 2021

27 October2021

Disclaimer

Certain statements made in this Presentation may include forward-looking statements. These statements relate to the Company's expectations, beliefs, intentions or strategies regarding the future. The forward-looking statements reflect the Company's current views and assumptions with respect to future events and are subject to risks and uncertainties.

All though the Company believes that its expectations and the Presentation are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in the Presentation.

Carasent ASA is making no representations or warranty, expressed or implied, as to the accuracy, reliability or completeness of the Presentation, and neither Carasent ASA, nor any of its directors, officers, employees or advisors will have any liability to you or any other person resulting from your use.

Q3 2021 summary

4

6

Revised guidance to 30 – 35% organic growth for Evimeria and Avans Soma (from 35%) due to delayed revenues from new customers backlog ³

and 29% of Evimeria & Avans Soma

Continued strong order inflow and

Raised NOK 420 million in private placement opportunities ⁵

Active pipeline of new M&A

Carasent at a glance

• Cloud-based proprietary medical record software solution for the private healthcare segment
• Broad ecosystem of integrated third party services
• Two acquisitions completed during the last year, including Avans Soma in December 2020 and Metodika in May 2021
• Significant opportunity to expand organically and through M&A:
  • New products and services
  • New geographies
  • New segments

Consistent track-record of growth

Overall market trends

DRIVERS

PROBLEM

The need for high-quality healthcare at lower cost to society has never been greater

The healthcare industry is facing underlying structural issues

Digitalization is transforming healthcare

Broadening our offering through acquisitions…

…with aim of becoming "one Carasent" –unlocking synergies

Investment highlights

1

2

4

5

Exposure to an attractive niche segment of the non-cyclical Nordic e-health market

Proven track record of revenue and earnings growth

Potential for accelerated growth and expansion into new services, segments and geographies

Management team with proven track record

Financial Review

Q3 2021 –Summary

1: Adjusted for non-recurring items, including acquisition costs

Organic growth of 26% for the group in Q3

Delayed revenues from new customers affecting growth

2021 2020

Contracted ARR – new clinics Entry point license, cumulative (NOKm)

Reported revenue – new clinics License revenue (NOKm) 0.1 0.3 0.6 0.2 0.4 0.5 Q1 Q2 Q3

• Strong momentum within new sales
• Revenue postponed by delayed implementation processes
• Customers focus on pandemic related activities, affecting 2021 growth rates
• Upside to entry point license from integrated services and volume growth

Note: Evimeria figures

Organicgrowthdriven by loyaland consistentlygrowingcustomerbase

Scalable model with increasing margins

Improving margins driven by scalable operating cost base

Outlook

Outlook

• New guidance for 2021:
  • 30 35 % from previous of 35% organic revenue growth for Evimeria and Avans Soma
  • Guidance of 40% EBITDA margin maintained for Evimeria and Avans Soma
• While organic growth rates within the quarter were lower than our expectations, the long-term prospects remain intact
• M&A pipeline is active and we remain disciplined in our approach

Multiple avenuesfor furthergrowth

Broad field of both organic and structural growth opportunities available